We are live on ! Find out more
VVA

Vida Ventures Advisors Portfolio holdings

AUM $29.4M
1-Year Est. Return 93.58%
This Fund
S&P 500
This Quarter Est. Return
+8.74%
1 Year Est. Return
+93.58%
3 Year Est. Return
+153.74%
5 Year Est. Return
+14.63%
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$96M
Cap. Flow
+$72.6M
Cap. Flow %
40.35%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
KYTX icon
Kyverna Therapeutics
KYTX
+$126M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$37.7M
2
LIAN
LianBio American Depositary Shares
LIAN
+$10.2M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$5.23M
4
IMA
ImageneBio Inc
IMA
+$444K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYTX icon
1
Kyverna Therapeutics
KYTX
$481M
$112M 62.43%
+4,523,924
New +$126M
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$44.4M 24.68%
3,931,818
– –
DYN icon
3
Dyne Therapeutics
DYN
$4.24B
$11.6M 6.43%
407,499
-1,667,288
-80% -$37.7M
ALLO icon
4
Allogene Therapeutics
ALLO
$604M
$8.04M 4.47%
1,798,163
– –
KRON
5
DELISTED
Kronos Bio
KRON
$3.59M 2%
2,765,314
– –
IMA
6
ImageneBio Inc
IMA
$63.2M
– –
-18,766
Closed -$444K
KNTE
7
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-2,207,772
Closed -$5.23M
LIAN
8
DELISTED
LianBio American Depositary Shares
LIAN
– –
-2,282,084
Closed -$10.2M

Similar funds

NC
Nucleo Capital Sao Paulo, Sp, Brazil $29.1M AUM 59.16% 1-Year Est. Return
PIM
Pinnacle Investment Management Hong Kong $28.9M AUM 32% 1-Year Est. Return
NCPI
NewView Capital Partners I Burlingame, California $28M AUM 10.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
RE
ROB Exploration New York $27.3M AUM 13.99% 1-Year Est. Return
VM
Valinor Management New York $32.2M AUM 44.16% 1-Year Est. Return
BCA
Burren Capital Advisors Gibraltar $33M AUM 47.67% 1-Year Est. Return
VCM
Vector Capital Management San Francisco, California $24.4M AUM 14.95% 1-Year Est. Return

Vida Ventures Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Vida Ventures Advisors held 8 positions worth $180M, up 114% from $84M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Vida Ventures Advisors deployed $72.6M of net new capital in Q1 2024, opening 1 new position. Its largest new stake was Kyverna Therapeutics: 4,523,924 shares worth $112M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $37.7M trimmed.

  • Vida Ventures Advisors's largest Q1 2024 buy was Kyverna Therapeutics: 4,523,924 shares worth $112M.
  • Vida Ventures Advisors's biggest Q1 2024 reduction was Dyne Therapeutics, cutting an estimated $37.7M.
  • Vida Ventures Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $10.2M.
  • Vida Ventures Advisors's ten largest holdings make up 100% of its $180M portfolio in Q1 2024.
  • Vida Ventures Advisors opened 1 new position and closed 3 in Q1 2024.
  • Vida Ventures Advisors's portfolio value rose 114% quarter-over-quarter to $180M.

Based on Vida Ventures Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.